ATE304528T1 - Verbindungen mit wachstumshormon-freisetzenden eigenschaften - Google Patents

Verbindungen mit wachstumshormon-freisetzenden eigenschaften

Info

Publication number
ATE304528T1
ATE304528T1 AT01123155T AT01123155T ATE304528T1 AT E304528 T1 ATE304528 T1 AT E304528T1 AT 01123155 T AT01123155 T AT 01123155T AT 01123155 T AT01123155 T AT 01123155T AT E304528 T1 ATE304528 T1 AT E304528T1
Authority
AT
Austria
Prior art keywords
compounds
growth hormone
hormone releasing
releasing properties
formula
Prior art date
Application number
AT01123155T
Other languages
German (de)
English (en)
Inventor
Bernd Peschke
Michael Ankersen
Thomas Kruse Hansen
Henning Thoegersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE304528T1 publication Critical patent/ATE304528T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06Compounds containing any of the groups, e.g. semicarbazides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01123155T 1996-07-22 1997-07-17 Verbindungen mit wachstumshormon-freisetzenden eigenschaften ATE304528T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK80396 1996-07-22

Publications (1)

Publication Number Publication Date
ATE304528T1 true ATE304528T1 (de) 2005-09-15

Family

ID=8097747

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01123155T ATE304528T1 (de) 1996-07-22 1997-07-17 Verbindungen mit wachstumshormon-freisetzenden eigenschaften
AT97930368T ATE218537T1 (de) 1996-07-22 1997-07-17 Verbindungen mit wachstumshormon freisetzenden eigenschaften

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97930368T ATE218537T1 (de) 1996-07-22 1997-07-17 Verbindungen mit wachstumshormon freisetzenden eigenschaften

Country Status (8)

Country Link
US (3) US5922770A (enExample)
EP (2) EP0923539B1 (enExample)
JP (1) JP4425992B2 (enExample)
AT (2) ATE304528T1 (enExample)
AU (1) AU3434697A (enExample)
DE (2) DE69734215T2 (enExample)
WO (1) WO1998003473A1 (enExample)
ZA (1) ZA976371B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1998058950A1 (en) * 1997-06-20 1998-12-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU757217B2 (en) * 1998-05-11 2003-02-06 Helsinn Healthcare Sa Compounds with growth hormone releasing properties
TW450954B (en) * 1998-05-14 2001-08-21 Pharmacia & Amp Upjohn Company Phenylsulfonamide-phenylethylamines useful as dopamine receptors
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU771644B2 (en) * 1998-06-30 2004-04-01 Helsinn Healthcare Sa Compounds with growth hormone releasing properties
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
AU759022B2 (en) 1999-02-18 2003-04-03 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
EP1265849B1 (en) 2000-03-23 2006-10-25 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
US7087632B2 (en) * 2001-03-05 2006-08-08 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
US6613801B2 (en) * 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
JP2004502664A (ja) * 2000-06-30 2004-01-29 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病処置用化合物
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
EP1666452A2 (en) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
DE60211866T2 (de) * 2001-02-16 2007-06-14 Allelix Neuroscience Inc. Thiophen substituierte amin derivate als glyt-1 inhibitoren
CN1494425B (zh) * 2001-03-05 2011-12-07 特兰斯泰克制药公司 用作治疗剂的羧酰胺衍生物
EP1401452A1 (en) * 2001-06-27 2004-03-31 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in the treatment of alzheimer's disease
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
ATE435202T1 (de) 2002-01-11 2009-07-15 Daiichi Sankyo Co Ltd Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung
US7230133B2 (en) 2003-05-01 2007-06-12 Bristol-Myers Squibb Company Malonamides and malonamide derivatives as modulators of chemokine receptor activity
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
RU2332212C2 (ru) 2004-02-24 2008-08-27 Санкио Компани, Лимитед Аминоспирт
US20050261201A1 (en) * 2004-03-30 2005-11-24 Rejuvenon Corporation Method of reducing C-reactive protein using growth hormone secretagogues
CN103772483A (zh) * 2004-06-29 2014-05-07 赫尔辛医疗股份公司 (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形
PT1789067E (pt) * 2004-08-12 2012-08-06 Helsinn Healthcare Sa Utilização de hormona do crescimento secretagogo para a estimulação da motilidade do sistema gastrointestinal
EP1942193A4 (en) 2005-08-25 2010-10-27 Ube Industries METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE (S OR R) -AMINOIC ACID OR AN OPTICALLY ACTIVE (S OR R) -α-AMINO-ACID ESTER
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
JP2010518158A (ja) * 2007-02-13 2010-05-27 ヘルシン セラピューティクス(ユー.エス.),インコーポレイティド 成長ホルモン分泌促進物質を用いた細胞増殖性障害の治療方法
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
ES2467923T3 (es) 2009-09-30 2014-06-13 Transtech Pharma, Llc Derivados de imidazol substituidos para el tratamiento de la enfermedad de Alzheimer
RU2582678C2 (ru) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
WO2013123266A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
CN104812384B (zh) 2012-11-01 2020-09-18 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2017139317A1 (en) 2016-02-09 2017-08-17 Lumeova, Inc Ultra-wideband, wireless optical high speed communication devices and systems
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
JP7464591B2 (ja) 2018-10-10 2024-04-09 ブイティーブイ・セラピューティクス・エルエルシー [3-(4-{2-ブチル-1-[4-(4-クロロ-フェノキシ)-フェニル]-1h-イミダゾール-4-イル}-フェノキシ)-プロピル]-ジエチル-アミンの代謝産物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ277486A (en) * 1993-12-23 1997-03-24 Novo Nordisk As Synthetic peptides with growth hormone releasing properties
MY113488A (en) * 1995-01-27 2002-03-30 Novo Nordisk As Compounds with growth hormone releasing properties
CN1211991A (zh) * 1995-12-22 1999-03-24 诺沃挪第克公司 具有生长激素释放性质的化合物

Also Published As

Publication number Publication date
DE69713109D1 (de) 2002-07-11
ZA976371B (en) 1998-01-22
EP0923539A1 (en) 1999-06-23
JP4425992B2 (ja) 2010-03-03
EP1184370B1 (en) 2005-09-14
DE69713109T2 (de) 2003-01-02
US5922770A (en) 1999-07-13
EP1184370A2 (en) 2002-03-06
ATE218537T1 (de) 2002-06-15
US6274584B1 (en) 2001-08-14
DE69734215D1 (de) 2005-10-20
EP1184370A3 (en) 2002-03-27
WO1998003473A1 (en) 1998-01-29
AU3434697A (en) 1998-02-10
JP2000515517A (ja) 2000-11-21
EP0923539B1 (en) 2002-06-05
DE69734215T2 (de) 2006-06-29
US6127354A (en) 2000-10-03

Similar Documents

Publication Publication Date Title
ATE218537T1 (de) Verbindungen mit wachstumshormon freisetzenden eigenschaften
MY113488A (en) Compounds with growth hormone releasing properties
RU94016393A (ru) Пептиды, обладающие способностью к стимулированию высвобождения гормона роста, способ получения, фармацевтическая композиция, способ лечения
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
DE69333607D1 (de) Vorrichtung zur Herstellung von vorgefüllten, sterilen Abgabevorrichtungen
SG158731A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
SE9401406L (sv) Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma
DE3382458D1 (de) Haarwuchsmittel.
IT8619055A0 (it) Composizioni farmaceutiche comprendenti peptidi del gruppo colecistochinina-cerulina per il trattamento terapeutico degli statidi shock e dell'insufficienza respiratoria e cardiocircolatoria.
DK0562705T3 (da) Anvendelse af L-deprenyl til fremstilling af et lægemiddel til behandling af Cushings sygdom
DE60018409D1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
DE69929616D1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
GR3019774T3 (en) Piperidylmethyl substituted chroman derivatives as agents for the treatment of diseases of the central nervous system
GR3032224T3 (en) Therapeutic agent for threatened abortion.
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
CO4930262A1 (es) Producto farmaceutico cristalino, su preparacion y uso como sustancia terapeutica
NO166280C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n,n'-disubstituerte ureaer.
NO970185D0 (no) Anvendelse av (S)-adenosyl-L-metionin (SAMe) og dets fysiologisk kompatible salter for behandling av reperfusjonsskade utlöst av temporær-fokal-ischemi
FI102810B1 (fi) Aine eläimen ihon käsittelyyn
AP1629A (en) Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes.
RU2001113054A (ru) Способ лечения послеродового острого гнойно-катарального эндометрита коров
MX9800686A (es) Nueva proteina hmw humana mp52s.
WO2001068693A8 (fr) Nouveau polypeptide, proteine humaine de reception cannabinoide 7, et polynucleotide codant pour ce polypeptide
RU2001123759A (ru) Способ лечения одонтогенного остеомиелита, осложненного флегмоной
FI935575A7 (fi) 3-(kinolin-6-yylimetyyli)-4H-imidatsol-4-onijohdannaisia, menetelmä niiden valmistamiseksi ja niiden terapeuttinen käyttö

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties